Table I Differentially expressed proteins and their relative abundance in 48 hours after treatment (in parentheses). FDR-corrected p values (q-values) <0.05 were used to select differentially expressed proteins. Presented proteins have treated/conrol ratios outside the range of two standard deviations from the mean (0.72–1.30)
Positive control proteinsMetabolic proteins
High-galactose-no-glucose mediaSLC2A1 (2.0)ALDOC (1.7)
HSPA5 (1.7)
HYOU1 (1.4)
HypoxiaSLC2A1 (3.0)aPGR (0.5)ALDOC (3.1)aFBP2 (0.7)
GREB1 (0.6)GPI (1.9)
LDHA (1.9)a
PGK1 (1.8)a
PFKP (1.7)a
SLC7A5 (1.7)
ALDOA (1.5)a
SDHA (1.5)
PKM1/M2 (1.4)a
GAPDH (1.4)a
ENO1 (1.3)a
PGAM1 (1.3)a
Estradiol stimulationTFF1 (5.7)bSLC1A5 (1.4)FBP1 (0.6)b
PGR (4.1)bFBP2 (0.6)b
GREB1 (4.1)b
TFRC (3.1)
TPD52L1 (2.8)b
MCF-10AGLUD1 (5.4)TFF1 (0.01)
LDHA (4.9)FBP1 (0.01)
SDHB (3.2)FBP2 (0.1)
UGP2 (2.8)IDH2 (0.1)
FH (2.4)G6PD (0.1)
PGM2 (2.2)GALK1(0.1)
HK1 (2.2)GREB1 (0.2)
TUBB2C (1.9)TPD52L1 (0.2)
IDH3G (1.9)SLC1A5 (0.2)
PDHA1 (1.9)PES1 (0.2)
PDHB (1.8)TFRC (0.3)
TUBB (1.7)PCK2 (0.3)
ACO2 (1.7)PFKL (0.3)
SUCLA2 (1.7)RPIA (0.3)
DLAT (1.6)ALDOC (0.4)
PGD (0.4)
HSP90AB1 (0.5)
HYOU1 (0.5)
PGR (0.5)
GAPDH (0.6)
RPL6 (0.6)
SUCLG2 (0.6)
ALDOA (0.7)
RPL27A (0.7)
  • a Promoters or enhancers of these genes have hypoxia-responsive elements (HRE).

  • b Promoters or enhancers of these genes have estrogen-responsive elements (ERE).